Galenica AG to continue its sustained growth in 2025

In the third quarter of 2025, Galenica AG recorded sales growth of 4.7% to CHF 2,999.7 million. This increase was primarily driven by strong demand for prescription drugs and dietary supplements. The "Products & Care" and "Logistics & IT" segments each recorded sales growth of 5.0%.

The recent acquisition of Labor Team has contributed to the company's financial performance, enabling it to raise its financial forecasts. Galenica now anticipates annual sales growth of between 4% and 6%, and an EBIT increase of between 10% and 12%.

The Retail sector, particularly local pharmacies, also benefited from network expansion, recording organic growth of 3.4%. Pharmacy health services saw significant growth, with a 17% increase in services provided over the first nine months of the year.